Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 26
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Impact of an Online Training Program in Smoking Cessation Interventions in Hospitals

  • Martínez, Cristina
  • Castellano, Yolanda
  • Andres, Ana
  • Fu, Marcela
  • Feliu, Ariadna
  • Antón, Laura
  • Ballbè, Montse
  • Fernández, Paz
  • Cabrera, Sandra
  • Riccobene, Ana
  • Gavilan, Eva
  • Baena, Antoni
  • Margalef, Mercè
  • Tigova, Olena
  • Quirós, Núria
  • Guillen, Olga
  • Company, Assumpta
  • Fernández, Esteve
Purpose To assess changes in the self-reported performance of smoking cessation interventions according to the 5A's model (Ask; Advise; Assess; Assist; and Arrange follow-up) among clinicians; and to identify the main barriers and facilitators in smoking cessation implementation before and after an online smoking cessation training program. Design Pre-post evaluation. Methods We assessed self-reported smoking cessation interventions in the implementation of the 5A's model among clinicians working in Catalan hospitals (Spain). In addition, we assessed individual-, behavioral-, and organizational-level factors that act as barriers and facilitators in the implementation of the 5A's model. We used a questionnaire of 63 items reflecting each of the 5A's performance (scored from 0 = none to 10 = most possible). The questionnaire was completed both immediately before and 6 months after the training. We analyzed the data of those participants who had a clinical role and answered pre- and post-questionnaires. We used the nonparametric test for paired data (Wilcoxon) to examine changes in scores. Findings A total of 127 clinicians completed the pre-post questionnaire; 63.0% were registered nurses, 17.3% were nursing assistants, 7.9% were physicians, and 11.8% were other professionals (p < .001). Overall, there were significant increases in the implementation of the assist component (from a score of 4.5 to 5.2; p < .003) and arrange a follow-up component (from 3.6 to 4.5; p < .001) of the intervention. Scores in the perception of the level of overall preparation, preparedness in using smoking cessation drugs, level of competence, and organizational recognition improved (p < .001) at the follow-up; however, the score in the perception that implementing smoking cessation is part of their job decreased (from 6.3 to 4.4; p < .001). Conclusions The online training had a positive impact on the implementation of assist and arrange follow-up components. Although self-preparedness in the management of smokers increased, the motivation and involvement of key professionals decreased. Organizational factors related to the incorporation of resources (such as protocols, records, etc.) should be improved for the correct progression of smoking cessation interventions within the institutions. Clinical Relevance Smoking cessation training programs should incorporate some motivational content to increase the engagement of health professionals in smoking cessation interventions in their clinical practice., info:eu-repo/semantics/acceptedVersion
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Percepciones del envase neutro del tabaco entre fumadores y no fumadores en Andalucía (España)

  • Lacave-García, B.
  • Rey-Pino, J.M.
  • Gallopel-Morvan, K.
  • Moodie, C.
  • Fernández, E.
  • Nerín, I.
Objectives: Each year tobacco is responsible for 650, 000 deaths in Europe and 55, 000 in Spain. With tobacco advertising and promotion banned in Spain and most of Europe, the last bastion of marketing is the packaging. Plain tobacco packaging —which involves packs having a standardised appearance— has been proposed to counter this. The objective of this study is to research perceptions arising from the plain packaging of tobacco products. Methods: We employed a qualitative research methodology -focus groups- with smokers and non-smokers in in two medium-sized Andalusian towns (Spain). Results: Results show the importance of plain cigarette packaging as a form of promotion, particularly among women and young people, how pack colour influences product perceptions, and how removing full branding increases the salience of the warnings. Conclusions: Plain packaging, combined with pictorial health warnings, may reduce the capacity of packaging to be distinctive and a badge product. Altering pack design in such a way would make it more difficult for tobacco companies to create a favourable image of their brands and may help to reinforce the ability of the population to protect themselves from the dangers of smoking.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Sustained high serum caspase-3 concentrations and mortality in septic patients

  • Lorente, L.
  • Martín, M.M.
  • Pérez-Cejas, A.
  • González-Rivero, A.F.
  • López, R.O.
  • Ferreres, J.
  • Solé-Violán, J.
  • Labarta, L.
  • Díaz, C.
  • Palmero, S.
  • Jiménez, A.
Caspase-3 is the main executor of the apoptotic process. Higher serum caspase-3 concentrations in non-survivor compared to survivor septic patients have been found. The objectives of this work (with the increase of sample size to 308 patients, and the determination of serum caspase-3 concentrations also on days 4 and 8 of diagnosis of severe sepsis) were to know whether an association between serum caspase-3 concentrationss during the first week, degree of apoptosis, sepsis severity, and sepsis mortality exists. We collected serum samples of 308 patients with severe sepsis from eight intensive care units on days 1, 4 and 8 to measure concentrations of caspase-3 and caspase-cleaved cytokeratin (CCCK)-18 (to assess degree of apoptosis). End point was 30-day mortality. We found higher serum concentrations of caspase-3 and CCCK-18 in non-survivors compared to survivors on days 1 (p < 0.001), 4 (p < 0.001), and 8 (p < 0.001). We found an association between serum caspase-3 concentrations on days 1, 4 and 8 of severe sepsis diagnosis and serum CCCK-18 concentrations (p < 0.001), SOFA (p < 0.001), serum acid lactic concentrations (p < 0.001), and 30-day sepsis mortality (p < 0.001). The new findings of this work were that an association between serum caspase-3 concentrations during the first week, apoptosis degree, sepsis severity, and sepsis mortality exists.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of an Online Training Program in Smoking Cessation Interventions in Hospitals

  • Martínez, Cristina
  • Castellano, Yolanda
  • Andres, Ana
  • Fu, Marcela
  • Feliu, Ariadna
  • Antón, Laura
  • Ballbè, Montse
  • Fernández, Paz
  • Cabrera, Sandra
  • Riccobene, Ana
  • Gavilan, Eva
  • Baena, Antoni
  • Margalef, Mercè
  • Tigova, Olena
  • Quirós, Núria
  • Guillen, Olga
  • Company, Assumpta
  • Fernández, Esteve
Purpose To assess changes in the self-reported performance of smoking cessation interventions according to the 5A's model (Ask; Advise; Assess; Assist; and Arrange follow-up) among clinicians; and to identify the main barriers and facilitators in smoking cessation implementation before and after an online smoking cessation training program. Design Pre-post evaluation. Methods We assessed self-reported smoking cessation interventions in the implementation of the 5A's model among clinicians working in Catalan hospitals (Spain). In addition, we assessed individual-, behavioral-, and organizational-level factors that act as barriers and facilitators in the implementation of the 5A's model. We used a questionnaire of 63 items reflecting each of the 5A's performance (scored from 0 = none to 10 = most possible). The questionnaire was completed both immediately before and 6 months after the training. We analyzed the data of those participants who had a clinical role and answered pre- and post-questionnaires. We used the nonparametric test for paired data (Wilcoxon) to examine changes in scores. Findings A total of 127 clinicians completed the pre-post questionnaire; 63.0% were registered nurses, 17.3% were nursing assistants, 7.9% were physicians, and 11.8% were other professionals (p < .001). Overall, there were significant increases in the implementation of the assist component (from a score of 4.5 to 5.2; p < .003) and arrange a follow-up component (from 3.6 to 4.5; p < .001) of the intervention. Scores in the perception of the level of overall preparation, preparedness in using smoking cessation drugs, level of competence, and organizational recognition improved (p < .001) at the follow-up; however, the score in the perception that implementing smoking cessation is part of their job decreased (from 6.3 to 4.4; p < .001). Conclusions The online training had a positive impact on the implementation of assist and arrange follow-up components. Although self-preparedness in the management of smokers increased, the motivation and involvement of key professionals decreased. Organizational factors related to the incorporation of resources (such as protocols, records, etc.) should be improved for the correct progression of smoking cessation interventions within the institutions. Clinical Relevance Smoking cessation training programs should incorporate some motivational content to increase the engagement of health professionals in smoking cessation interventions in their clinical practice., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute and subacute effects of oropharyngeal sensory stimulation with TRPV1 agonists in older patients with oropharyngeal dysphagia, a biomechanical and neurophysiological randomized pilot study

  • Tomsen, Noemí|||0000-0001-7149-7948
  • Ortega, Omar|||0000-0001-6178-3748
  • Rofes, Laia|||0000-0002-1628-5253
  • Arreola, Viridiana|||0000-0003-3913-317X
  • Martín-Martínez, Alberto|||0000-0002-6805-764X
  • Mundet, Lluís|||0000-0001-9091-8998
  • Clavé i Civit, Pere|||0000-0002-0696-8560
Background: Older people with oropharyngeal dysphagia (OD) present a decline in pharyngeal sensory function. The aim of this proof-of-concept study was to assess the biomechanical and neurophysiological effects of acute and subacute oropharyngeal sensory stimulation with transient receptor potential vanilloid 1 (TRPV1) agonists (capsaicinoids) in older patients with OD. Methods: We studied the effect of a single dose versus multiple doses (2 weeks) of oral capsaicin treatment (10 M) or placebo in 28 older patients with OD (81.2 ± 4.6 years) using videofluoroscopy (penetration-aspiration scale [PAS], timing of swallow response) and electroencephalography (EEG) (latency and amplitude of pharyngeal event-related potential [ERP]). Results: Acute stimulation by capsaicinoids 10 M did not improve swallow function and did not produce significant changes in pharyngeal ERP. In contrast, after 10 days of treatment, patients presented a clinically relevant and statistically significant reduction in the laryngeal vestibule closure (LVC) time (22.5%, p = 0.042), and in the PAS (24.2%, p = 0.038), compared with the placebo group. EEG results showed a reduction in the latency of the N1 peak (28.6%, p = 0.007) and an increase of the amplitude of the P1-N2 (59.4%, p = 0.038) and the N2-P2 (43.6%, p = 0.050) peaks. We observed a strong and significant correlation between the reduction in the latency of the N1 peak and change in LVC time after subacute treatment (r = 0.750, p = 0.003). Conclusions: After 2 weeks of treatment, oropharyngeal sensory stimulation with capsaicinoids induced cortical changes that were correlated with improvements in swallowing biomechanics in older patients with OD. These results further show that sensory stimulation by TRPV1 agonists can become a useful pharmacological treatment for older patients with OD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of a gum-based thickener on the safety of swallowing in patients with poststroke oropharyngeal dysphagia

  • Bolivar-Prados, Mireia|||0000-0002-8896-1150
  • Rofes, L.
  • Arreola, Viridiana|||0000-0003-3913-317X
  • Guida, S.
  • Nascimento, Weslania Viviane|||0000-0003-1267-3475
  • Martín-Martínez, Alberto|||0000-0002-6805-764X
  • Vilardell, N.|||0000-0002-1357-9889
  • Ortega, Omar|||0000-0001-6178-3748
  • Ripken, D.
  • Lansink, M.
  • Clavé i Civit, Pere|||0000-0002-0696-8560
Background: Increasing viscosity with thickening agents is a valid therapeutic strategy for oropharyngeal dysphagia (OD). To assess the therapeutic effect of a xanthan gum-based thickener (Nutilis Clear) at six viscosities compared with thin liquid in poststroke OD (PSOD) patients. Methods: A total of 120 patients with PSOD were studied in this controlled, multiple-dose, fixed-order, and single-blind study using videofluoroscopy (VFSS). A series of boluses of 10 mL thin liquid and 2000, 1400, 800, 450, 250, and 150 mPa s viscosities were given in duplicate, interrupted in case of aspiration. We assessed the safety and efficacy of swallow and the kinematics of the swallow response. Key Results: A total of 41.2% patients had safe swallow at thin liquid which significantly increased for all viscosities from 71.9% at 150 mPa s to 95.6% at 1400 mPa s (P <.001). PAS score (3.7 ± 2.3) at thin liquid was also reduced by increasing bolus viscosity (P <.001). The prevalence of patients with aspiration at thin liquid was 17.5% and decreased at all viscosities (P <.01), except at 150 mPa s. Increasing viscosity shortened time to laryngeal vestibule closure (LVC) at all viscosities (P <.01) and reduced bolus velocity at ≥450 mPa s (P <.05). The prevalence of patients with pharyngeal residue at each viscosity 37.7%-44.7% was similar to that at thin liquid (41.2%). Conclusions and Inferences: The prevalence of unsafe swallow with thin liquids is very high in PSOD. Increasing shear bolus viscosity with this xanthan gum-based thickener significantly increased the safety of swallow in patients with PSOD in a viscosity-dependent manner without increasing the prevalence of pharyngeal residue.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Secondhand smoke exposure assessment in outdoor hospitality venues across 11 European countries

  • Henderson, Elisabet|||0000-0002-4114-943X
  • Continente, Xavier|||0000-0003-4888-2754
  • Fernández, Esteve|||0000-0003-4239-723X
  • Tigova, Olena|||0000-0002-4002-116X
  • Cortés-Francisco, Nuria|||0000-0002-1627-9718
  • Gallus, Silvano|||0000-0002-8967-0400
  • Lugo, Alessandra|||0000-0002-4297-6496
  • Semple, Sean|||0000-0002-0462-7295
  • Dobson, Ruaraidh|||0000-0001-8136-8373
  • Clancy, Luke|||0000-0003-2407-2263
  • Keogan, Sheila
  • Ruprecht, Ario
  • Borgini, Alessandro|||0000-0002-5167-4297
  • Tzortzi, Anna S|||0000-0003-2420-7922
  • Vyzikidou, Vergina Konstantina
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • López-Nicolás, Ángel|||0000-0003-3112-7779
  • Soriano, Joan B..|||0000-0001-9740-2994
  • Geshanova, Gergana
  • Osman, Joseph
  • Mons, Ute|||0000-0003-1764-6783
  • Przewozniak, Krzysztof
  • Precioso, José|||0000-0002-7889-8290
  • Brad, Ramona
  • López, Maria J.
Due to partial or poorly enforced restrictions secondhand tobacco smoke (SHS) is still present in outdoor hospitality venues in many European countries. This study aimed to assess SHS concentrations in outdoor hospitality venues across Europe and identify contextual exposure determinants. Cross-sectional study. We measured airborne nicotine and evidence of tobacco use in terraces of bars, cafeterias, and pubs from 11 European countries in 2017-2018. Sites were selected considering area-level socioeconomic indicators and half were visited during nighttime. We noted the smell of smoke, presence of smokers, cigarette butts, ashtrays, and number of physical covers. Contextual determinants included national smoke-free policies for the hospitality sector, the Tobacco Control Scale score (2016), and the national smoking prevalence (2017-2018). We computed medians and interquartile ranges (IQR) of nicotine concentrations and used multivariate analyses to characterize the exposure determinants. Nicotine was present in 93.6% of the 220 sites explored. Overall concentrations were 0.85 (IQR:0.30-3.74) μg/m 3 and increased during nighttime (1.45 IQR:0.65-4.79 μg/m 3), in enclosed venues (2.97 IQR:0.80-5.80 μg/m 3), in venues with more than two smokers (2.79 IQR:1.03-6.30 μg/m 3), in venues in countries with total indoor smoking bans (1.20 IQR:0.47-4.85 μg/m 3), and in venues in countries with higher smoking prevalence (1.32 IQR:0.49-5.34 μg/m 3). In multivariate analyses, nicotine concentrations were also positively associated with the observed number of cigarette butts. In venues with more than two smokers, SHS levels did not significantly vary with the venues' degree of enclosure. Our results suggest that current restrictions in outdoor hospitality venues across Europe have a limited protective effect and justify the adoption of total smoking bans in outdoor areas of hospitality venues.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of prenatal cerebral and cardiac metabolic changes in a rabbit model of fetal growth restriction based on 13 C-labelled substrate infusions and ex vivo multinuclear HRMAS

  • Simoes, Rui Vasco|||0000-0001-7574-4723
  • Cabañas Egaña, Miquel|||0000-0003-0104-0197
  • Loreiro, Carla
  • Illa, Miriam
  • Crispi, Fatima|||0000-0002-7422-5240
  • Gratacós, Eduard|||0000-0002-7405-7224
We have used a previously reported rabbit model of fetal growth restriction (FGR), reproducing perinatal neurodevelopmental and cardiovascular impairments, to investigate the main relative changes in cerebral and cardiac metabolism of term FGR fetuses during nutrient infusion. FGR was induced in 9 pregnant New Zealand rabbits at 25 days of gestation: one horn used as FGR, by partial ligation of uteroplacental vessels, and the contralateral as control (appropriate for gestation age, AGA). At 30 days of gestation, fasted mothers under anesthesia were infused i.v. with 1- 13 C-glucose (4 mothers), 2- 13 C-acetate (3 mothers), or not infused (2 mothers). Fetal brain and heart samples were quickly harvested and frozen down. Brain cortex and heart apex regions from 30 fetuses were studied ex vivo by HRMAS at 4°C, acquiring multinuclear 1D and 2D spectra. The data were processed, quantified by peak deconvolution or integration, and normalized to sample weight. Most of the total 13 C-labeling reaching the fetal brains/hearts (80-90%) was incorporated to alanine and lactate (cytosol), and to the glutamine-glutamate pool (mitochondria). Acetate-derived lactate (Lac C2C3) had a slower turnover in FGR brains (~ -20%). In FGR hearts, mitochondrial turnover of acetate-derived glutamine (Gln C4) was slower (-23%) and there was a stronger accumulation of phospholipid breakdown products (glycerophosphoethanolamine and glycerophosphocholine, +50%), resembling the profile of non-infused control hearts. Our results indicate specific functional changes in cerebral and cardiac metabolism of FGR fetuses under nutrient infusion, suggesting glial impairment and restricted mitochondrial metabolism concomitant with slower cell membrane turnover in cardiomyocytes, respectively. These prenatal metabolic changes underlie neurodevelopmental and cardiovascular problems observed in this FGR model and in clinical patients, paving the way for future studies aimed at evaluating metabolic function postnatally and in response to stress and/or treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Secondhand smoke presence in outdoor areas in 12 European countries

  • Henderson, Elisabet|||0000-0002-4114-943X
  • Lugo, Alessandra|||0000-0002-4297-6496
  • Liu, X.
  • Continente, Xavier|||0000-0003-4888-2754
  • Fernández, Esteve|||0000-0003-4239-723X
  • López Medina, María José|||0000-0003-4402-2239
  • Gallus, Silvano|||0000-0002-8967-0400
Introduction: Secondhand smoke (SHS) causes morbidity and mortality among non-smokers. Objectives: To investigate SHS presence in outdoor areas from 12 European countries and its association with country-level characteristics. Methods: Cross-sectional study performed in 2017-2018 within the TackSHS project. We conducted a face-to-face survey on a representative sample of the population aged 15 years and older from 12 European countries: Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania, and Spain. Out of 11,902 participants, 8,562 were non-smokers. SHS presence was assessed in selected outdoor areas and defined as respondents viewing someone smoking the last time they visited each setting within the last 6 months. A ranking score for outdoor SHS presence was assigned to each country based on the SHS presence in each setting. We used Spearman's correlation (r) and the Chi-squared tests to assess the relationship between SHS presence and country-level characteristics. Results: Except for children's playgrounds (39.5%; 95% confidence interval, CI: 37.6%-41.3%), more than half of non-smokers reported SHS presence in outdoor areas: schools (52.0%; 95%CI: 50.2%-53.7%), stadia (57.4%; 95%CI: 55.4%-59.4%), parks (67.3%; 95%CI: 66.0%-68.5%), hospitals (67.3%; 95%CI: 65.8%-68.7%), public transport stops (69.9%; 95%CI: 68.6%-71.2%), bar/restaurant terraces (71.4%; 95%CI: 70.2%-72.6%), and beaches (72.8%; 95%CI: 71.4%-74.1%). Residents in Latvia showed the highest overall outdoor SHS presence rank, followed by Greece, and Portugal. Outdoor SHS presence was directly correlated to the country's smoking prevalence (r = 0.64), and inversely correlated to the Tobacco Control Scale 2016 overall score (r = -0.62), the socio-demographic index 2017 (r = -0.56), and Gross Domestic Product per capita 2018 (r = -0.47) (p < 0.001). Conclusions: SHS presence is high in most outdoor areas in Europe, especially in countries with higher smoking prevalence and lower tobacco control performance. To address outdoor SHS exposure, our findings require considering smoking bans along with other strategies to reduce smoking prevalence.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Secondhand smoke exposure in outdoor children's playgrounds in 11 European countries

  • Henderson, Elisabet|||0000-0002-4114-943X
  • Continente, Xavier|||0000-0003-4888-2754
  • Fernández, Esteve|||0000-0003-4239-723X
  • Tigova, Olena|||0000-0002-4002-116X
  • Cortés-Francisco, Nuria|||0000-0002-1627-9718
  • Gallus, Silvano|||0000-0002-8967-0400
  • Lugo, Alessandra|||0000-0002-4297-6496
  • Semple, Sean|||0000-0002-0462-7295
  • O'Donnell, Rachel|||0000-0003-2713-1847
  • Clancy, Luke|||0000-0003-2407-2263
  • Keogan, Sheila
  • Ruprecht, Ario Alberto
  • Borgini, Alessandro|||0000-0002-5167-4297
  • Tzortzi, Anna S.|||0000-0003-2420-7922
  • Vyzikidou, Vergina Konstantina
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • López-Nicolás, Ángel|||0000-0003-3112-7779
  • Soriano, Joan B.|||0000-0001-9740-2994
  • Geshanova, Gergana
  • Osman, Joseph
  • Mons, Ute|||0000-0003-1764-6783
  • Przewozniak, Krzysztof
  • Precioso, José|||0000-0002-7889-8290
  • Brad, Ramona
  • López Medina, María José|||0000-0003-4402-2239
Introduction: Tobacco presence in outdoor children's playgrounds is concerning not only because it leads to secondhand smoke (SHS) exposure, but also cigarette butt pollution and tobacco normalization. Objectives: This study aimed to assess SHS exposure in children's playgrounds, according to area-level socioeconomic status (SES), smoke-free regulations, national smoking prevalence, and SHS exposure prevalence in playgrounds (2017-2018). Methods: We monitored vapor-phase nicotine concentration and tobacco-related variables in 20 different playgrounds in 11 European countries (n = 220 measurements) from March 2017 to April 2018. Playgrounds were selected according to area-level SES. Data on the number of people smoking, and cigarette butts inside the playground and on playground surroundings (<1 m away) were recorded. Playground smoking bans, the Tobacco Control Scale (TCS) score, national smoking prevalence and SHS exposure prevalence in playgrounds were used to group countries. To determine nicotine presence, we dichotomized concentrations using the limit of quantification as a cut-off point (0.06 μg/m). Nicotine median concentrations were compared using non-parametric tests, and nicotine presence and tobacco-related observational variables using the Chi-squared test. Results: Airborne nicotine presence was found in 40.6% of the playgrounds. Median nicotine concentration was <0.06 μg/m (Interquartile range: <0.06-0.125) and higher median concentrations were found in more deprived neighborhoods, non-regulated playgrounds, in countries with lower overall TCS scores, higher national smoking prevalence and higher SHS exposure prevalence in playgrounds. Overall, people were smoking in 19.6% of the playgrounds. More than half of playgrounds had cigarette butts visible inside (56.6%) and in the immediate vicinity (74.4%). Presence of butts inside playgrounds was higher in sites from a low area-level SES, in countries with low TCS scores, and greater smoking prevalence and SHS exposure prevalence (p<0.05). Conclusions: There is evidence of SHS exposure in children's playgrounds across Europe. These findings confirm the need for smoking bans in playgrounds and better enforcement in those countries with smoking bans in playgrounds.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado Kith, Óscar|||0000-0001-8372-2604
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Berenguer, Juan|||0000-0001-8541-8200
  • Medrano, Luz María|||0000-0003-3717-5384
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, María Ángeles|||0000-0002-1945-6169
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Navarro, Jordi|||0000-0002-7187-0367
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Resino, Salvador|||0000-0001-8783-0450
Objective: To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods: We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results: HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion: HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Tobacco control policies in the 21st century, achievements and open challenges

  • Peruga, Armando|||0000-0002-1138-3292
  • López Medina, María José|||0000-0003-4402-2239
  • Martínez, Cristina|||0000-0002-9368-1356
  • Fernández, Esteve|||0000-0003-4239-723X
Noncommunicable diseases (NCDs), including cancer, are responsible for almost 70% of all deaths worldwide. Tobacco use is a risk factor common to most NCDs. This article discusses tobacco control policies and highlights major achievements and open challenges to reduce smoking prevalence and attributable morbidity and mortality in the 21st century. The introduction of the WHO Framework Convention on Tobacco Control in 2005 has been a key achievement in the field and has already facilitated a drop in both smoking prevalence and exposure to secondhand smoke. Indicatively, the size of the worldwide population benefiting from at least one cost-effective tobacco control policy has quadrupled since 2007. In addition, plain cigarette packaging has been successfully introduced as a tobacco control policy, surmounting efforts of the tobacco industry to challenge this based on trade and investment law. Nevertheless, tobacco control still faces major challenges. Smoking prevalence needs to be further reduced in a rather expedited manner. Smoke-free environments should be extended, and the use of plain tobacco packaging with large pictorial health warnings for all tobacco products should be further promoted in some parts of the world. Some of these measures will require prompt determination and diligence. For example, bold political decisions are needed to significantly increase real prices of tobacco products through excise taxes, ban added ingredients that are currently used to increase the attractiveness of tobacco products and ban the tobacco industry's corporate social responsibility initiatives. Finally, the debate on harm reduction strategies for tobacco control still needs to be resolved.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Who smokes in europe? Data from 12 european countries in the tackshs survey (2017-2018)

  • Gallus, Silvano|||0000-0002-8967-0400
  • Lugo, Alessandra|||0000-0002-4297-6496
  • Liu, Xiaoqiu|||0000-0001-8620-6592
  • Behrakis, Panagiotis
  • Boffi, Roberto|||0000-0002-1657-1591
  • Bosetti, Cristina|||0000-0003-2090-4608
  • Carreras, Giulia|||0000-0002-1427-637X
  • Chatenoud, Liliane|||0000-0001-9599-8229
  • Clancy, Luke|||0000-0003-2407-2263
  • Continente, Xavier|||0000-0003-4888-2754
  • Dobson, Ruaraidh|||0000-0001-8136-8373
  • Effertz, Tobias
  • Filippidis, Filippos T.
  • Fu, Marcela|||0000-0002-4962-0927
  • Geshanova, Gergana
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • Keogan, Sheila
  • Ivanov, Hristo
  • López Medina, María José|||0000-0003-4402-2239
  • López-Nicolás, Ángel|||0000-0003-3112-7779
  • Precioso, José|||0000-0002-7889-8290
  • Przewozniak, Krzysztof
  • Radu-Loghin, Cornel|||0000-0002-9922-4535
  • Ruprecht, Ario Alberto
  • Semple, Sean|||0000-0002-0462-7295
  • Soriano, Joan B.|||0000-0001-9740-2994
  • Starchenko, Polina
  • Trapero-Bertran, Marta|||0000-0002-9233-1776
  • Tigova, Olena|||0000-0002-4002-116X
  • Tzortzi, Anna S.|||0000-0003-2420-7922
  • Vardavas, Constantine|||0000-0003-0171-9570
  • Vyzikidou, Vergina Konstantina
  • Colombo, Paolo
  • Fernández, Esteve|||0000-0003-4239-723X
Background: Population data on tobacco use and its determinants require continuous monitoring and careful inter-country comparison. We aimed to provide the most up-to-date estimates on tobacco smoking from a large cross-sectional survey, conducted in selected European countries. Methods: Within the TackSHS Project, a face-to-face survey on smoking was conducted in 2017-2018 in 12 countries: Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania, and Spain, representing around 80% of the 432 million European Union (EU) adult population. In each country, a representative sample of around 1,000 subjects aged 15 years and older was interviewed, for a total of 11,902 participants. Results: Overall, 25.9% of participants were current smokers (31.0% of men and 21.2% of women, P < 0.001), while 16.5% were former smokers. Smoking prevalence ranged from 18.9% in Italy to 37.0% in Bulgaria. It decreased with increasing age (compared to <45, multivariable odds ratio [OR] for ≥65 year, 0.31; 95% confidence interval [CI], 0.27-0.36), level of education (OR for low vs high, 1.32; 95% CI, 1.17-1.48) and self-rated household economic level (OR for low vs high, 2.05; 95% CI, 1.74-2.42). The same patterns were found in both sexes. Conclusions: These smoking prevalence estimates represent the most up-to-date evidence in Europe. From them, it can be derived that there are more than 112 million current smokers in the EU-28. Lower socio-economic status is a major determinant of smoking habit in both sexes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Use and Awareness of Heated Tobacco Products in Europe

  • Gallus, Silvano|||0000-0002-8967-0400
  • Lugo, Alessandra|||0000-0002-4297-6496
  • Liu, Xiaoqiu|||0000-0001-8620-6592
  • Borroni, Elisa
  • Clancy, Luke|||0000-0003-2407-2263
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • López Medina, María José|||0000-0003-4402-2239
  • Odone, Anna
  • Przewozniak, Krzysztof
  • Tigova, Olena|||0000-0002-4002-116X
  • van den Brandt, Piet A.
  • Vardavas, Constantine|||0000-0003-0171-9570
  • Fernández, Esteve|||0000-0003-4239-723X
Background: Heated tobacco products (HTP) are new forms of tobacco consumption with limited information available on their use among the general population. Our objective was to analyze the prevalence and associations of use of HTP across 11 countries in Europe. Methods: Within the TackSHS Project, in 2017-2018 we conducted a cross-sectional study with information on HTP use in the following countries: Bulgaria, England, France, Germany, Greece, Italy, Latvia, Poland, Portugal, Romania and Spain. In each country, face-to-face interviews were performed on a representative sample of around 1,000 subjects aged ≥15 years, for a total of 10,839 subjects. Results: Overall, 27.8% of study participants were aware of HTPs, 1.8% were ever HTP users (ranging from 0.6% in Spain to 8.3% in Greece), and 0.1% were current users. Men were more frequently HTP ever users than women (adjusted odds ratio [aOR] 1.47; 95% confidence interval [CI], 1.11-1.95). Ever HTP use was inversely related to age (P for trend <0.001) and more frequent in ex-smokers (compared with never smokers, aOR 4.32; 95% CI, 2.69-6.95) and current smokers (aOR 8.35; 95% CI, 5.67-12.28), and in electronic cigarette past users (compared with never users, aOR 5.48; 95% CI, 3.46-8.68) and current users (aOR 5.92; 95% CI, 3.73-9.40). Conclusions: In 2017-2018, HTP use was still limited in Europe among the general population; however, the dual use of these products, their high use among younger generations, and the interest of non-smokers in these products are worrying and indicate the need for close monitoring in terms of prevalence and the characteristics of users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients

  • Lennol, Matthew Paul
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Soria, Guadalupe
  • Aguado, Fernando|||0000-0002-0393-1308
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Measuring for change, A multi-centre pre-post trial of an air quality feedback intervention to promote smoke-free homes

  • Dobson, Ruaraidh|||0000-0001-8136-8373
  • O'donnell, R.
  • Tigova, Olena|||0000-0002-4002-116X
  • Fu, Marcela|||0000-0002-4962-0927
  • Enríquez, Marta
  • Fernández, Esteve|||0000-0003-4239-723X
  • Castellano, Yolanda|||0000-0003-4452-305X
  • Ballbè, Montse|||0000-0002-0747-0924
  • Amalia, Beladenta|||0000-0002-9718-2693
  • Paniello-Castillo, Blanca|||0000-0002-3754-6571
  • López Medina, María José|||0000-0003-4402-2239
  • Carreras, Giulia|||0000-0002-1427-637X
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • Verdi, S.
  • Borgini, Alessandro|||0000-0002-5167-4297
  • Tittarelli, Andrea|||0000-0002-8865-5129
  • Veronese, Chiara|||0000-0002-1414-342X
  • Ruprecht, A.
  • Vyzikidou, Vergina Konstantina
  • Tzortzi, Anna S.|||0000-0003-2420-7922
  • Vardavas, C.
  • Semple, Sean|||0000-0002-0462-7295
Second-hand smoke exposure in the home is a serious cause of ill-health for children. Behaviour change interventions have been developed to encourage parents to keep homes smoke-free. This study evaluates a novel air quality feedback intervention using remote air quality monitoring with SMS and email messaging to promote smoke-free homes among families from deprived areas. This paper presents a pre-post study of this intervention. Using internet connected monitors developed with the Dylos DC1700, daily SMS and weekly email feedback provided for 16 days to participants recruited in four European countries. Participants were recruited based on their stage of change, in order to target those most able to achieve smoke-free homes. The primary outcome measure was median change in mean fine particulate matter (PM) concentration between baseline and follow-up periods, while secondary outcome measures included change in time over the World Health Organisation (WHO) guideline limit for PM exposure over 24 h (25 µg/m) in those periods and the number of homes where PM concentrations reduced. Telephone interviews were conducted with participants in Scotland post-intervention to explore intervention experience and perceived effectiveness. Of 86 homes that completed the intervention study, 57 (66%) experienced pre-post reductions in measured PM. The median reduction experienced was 4.1 µg/m (a reduction of 19% from baseline, p = 0.008). Eight homes where concentrations were higher than the WHO guideline limit at baseline fell below that level at follow-up. In follow-up interviews, participants expressed positive views on the usefulness of air quality feedback. Household air quality monitoring with SMS and email feedback can lead to behaviour change and consequent reductions in SHS in homes, but within the context of our study few homes became totally smoke-free.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Abordando la exposición a las emisiones del tabaco y de los cigarrillos electrónicos, protocolo del proyecto TackSHS

  • Fernández, Esteve|||0000-0003-4239-723X
  • López Medina, María José|||0000-0003-4402-2239
  • Gallus, Silvano|||0000-0002-8967-0400
  • Semple, Sean|||0000-0002-0462-7295
  • Clancy, Luke|||0000-0003-2407-2263
  • Behrakis, Panagiotis
  • Ruprecht, Ario
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • López Nicolás, Ángel
  • Radu-Loghin, Cornet
  • Soriano, Joan B.|||0000-0001-9740-2994
  • Castellano, Yolanda|||0000-0003-4452-305X
  • Fu, Marcela|||0000-0002-4962-0927
  • Ballbè, Montse|||0000-0002-0747-0924
  • Amalia, Beladenta|||0000-0002-9718-2693
  • Tigova, Olena|||0000-0002-4002-116X
  • Continente, Xavier|||0000-0003-4888-2754
  • Arechavala, Teresa|||0000-0001-7946-1210
  • Henderson, Elisabet|||0000-0002-4114-943X
  • Lugo, Alessandra|||0000-0002-4297-6496
  • Liu, Xiaoqiu|||0000-0001-8620-6592
  • Bosetti, Cristina|||0000-0003-2090-4608
  • Davoli, Enrico
  • Colombo, Paolo
  • O'Donnell, Rachel|||0000-0003-2713-1847
  • Dobson, Ruaraidh|||0000-0001-8136-8373
  • Keogan, Sheila
  • Li, Shashsa
  • Breslin, Elizabeth
  • Byrne, Hannah
  • Tzortzi, Anna S.|||0000-0003-2420-7922
  • Vardavas, Constantine|||0000-0003-0171-9570
  • Konstantina Vyzikidou, Vergina
  • Teloniatis, Stephanie
  • Bakelas, Gerasimos
  • Mattiampa, George
  • Boffi, Roberto|||0000-0002-1657-1591
  • De Marco, Cinzia|||0000-0003-1153-270X
  • Borgini, Alessandro|||0000-0002-5167-4297
  • Veronese, Chiara|||0000-0002-1414-342X
  • Bertoldi, Martina
  • Tittarelli, Andrea|||0000-0002-8865-5129
  • Carreras, Giulia|||0000-0002-1427-637X
  • Cortini, Barbara
  • Verdi, Simona
  • Lachi, Alessio
  • Chellini, Elisabetta
  • Trapero-Bertran, Marta|||0000-0002-9233-1776
  • Celdrán Guerrero, Daniel
  • Nguyen, Dominick
  • Starchenko, Polina
  • Ancochea, Julio|||0000-0001-7451-4133
  • Alonso Pérez, Tamara|||0000-0002-6312-4575
  • Teresa Pastor, María
  • Erro, Marta
  • Roca, Ana
  • Pérez, Patricia
Objective: The TackSHS project aims to comprehensively elucidate the impact that exposure to second-hand smoke (SHS) from cigarettes and second-hand aerosols (SHA) from electronic cigarettes have on the respiratory health of the European population according to socioeconomic characteristics and other determinants. Method: The TackSHS project involves a series of coordinated studies carried out by 11 academic and public health organisations from six European countries. The project will investigate: a) the determinants of SHS and SHA exposure assessed at the individual level (surveys on representative general population samples) and in common environments (environmental sampling in specific settings); b) the overall disease burden, mortality and morbidity attributable to such exposure; and c) its economic impact in terms of direct health care costs. The project will also examine specific acute respiratory health changes in healthy individuals and patients with respiratory diseases exposed to SHS and SHA. In addition, the project will examine the effectiveness of a novel intervention to reduce SHS exposure in households where smoking is permitted. All these studies are inter-related and involve collaborative coordination among the participant organisations. Conclusion: The comprehensive, integrated approach of the TackSHS project will enable a significant step forward from the current status quo in the understanding of the impact of SHS and SHA exposure on health and provide the basis for health policy recommendations to help European countries to further reduce the harm caused by SHS and SHA exposure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Secondhand smoke exposure and other signs of tobacco consumption at outdoor entrances of primary schools in 11 European countries

  • Henderson, Elisabet|||0000-0002-4114-943X
  • Continente, Xavier|||0000-0003-4888-2754
  • Fernández, Esteve|||0000-0003-4239-723X
  • Tigova, Olena|||0000-0002-4002-116X
  • Cortés-Francisco, Nuria|||0000-0002-1627-9718
  • Gallus, Silvano|||0000-0002-8967-0400
  • Lugo, Alessandra|||0000-0002-4297-6496
  • Semple, Sean|||0000-0002-0462-7295
  • O'Donnell, Rachel|||0000-0003-2713-1847
  • Clancy, Luke|||0000-0003-2407-2263
  • Keogan, Sheila
  • Ruprecht, Ario
  • Borgini, Alessandro|||0000-0002-5167-4297
  • Tzortzi, Anna S|||0000-0003-2420-7922
  • Vyzikidou, Vergina Konstantina
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • López-Nicolás, Ángel|||0000-0003-3112-7779
  • Soriano, Joan B..|||0000-0001-9740-2994
  • Geshanova, Gergana
  • Osman, Joseph
  • Mons, Ute|||0000-0003-1764-6783
  • Przewozniak, Krzysztof
  • Precioso, José|||0000-0002-7889-8290
  • Brad, Ramona
  • López, Maria J.
Although smoking restrictions at child-related settings are progressively being adopted, school outdoor entrances are neglected in most smoke-free policies across Europe. To describe secondhand smoke (SHS) exposure and tobacco-related signs in outdoor entrances of primary schools in Europe according to area-level socioeconomic status (SES), smoke-free policy, national smoking prevalence, and geographical region. In this cross-sectional study we monitored vapor-phase nicotine concentrations at 220 school outdoor entrances in 11 European countries (March 2017-October 2018). To account for nicotine presence, we used the laboratory's limit of quantification of 0.06 μg/m as point threshold. We also recorded the presence of smell of smoke, people smoking, cigarette butts, and ashtrays. Half of the schools were in deprived areas. We grouped countries according to their Tobacco Control Scale (TCS) score, smoking prevalence (2017-2018), and United Nations M49 geographical region. There were detectable levels of nicotine in 45.9% of the outdoor entrances, in 29.1% smell of smoke, in 43.2% people smoking, in 75.0% discarded butts, and in 14.6% ashtrays. Median nicotine concentration was below the laboratory's limit of quantification <0.06 μg/m (Interquartile range:<0.06-0.119). We found higher SHS levels in countries with lower TCS scores, higher national smoking prevalence, and in the Southern and Eastern European regions. People smoking were more common in schools from lower area-level SES and in countries with lower TCS scores (p<0.05). Smoking at school outdoor entrances is a source of SHS exposure in Europe. These findings support the extension of smoking bans with a clear perimeter to the outdoor entrances of schools.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Von Wichmann, Miguel Ángel
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador|||0000-0001-8783-0450
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Miralles, Pilar
  • López, Juan Carlos
  • Parras, Francisco José
  • Padilla Ortega, Belén
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Carretero, S.
  • Bellón, José-María|||0000-0002-8492-1565
  • Bermejo, Javier|||0000-0002-5241-2758
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Pascual Pareja, J. Francisco
  • Zamora, Francisco
  • Peña, Jose M.
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Díaz, Marta
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, Jaime|||0000-0001-6934-4619
  • Bustinduy, M.J.
  • Iribarren, José Antonio
  • Rodríguez-Arrondo, F.
  • Eynde, E.Van den
  • Pérez, M.
  • Ribera, E.
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, A.
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Sanfrutos, M.A.
  • Moreno, S.
  • Quereda, Carmen
  • Arranz, A.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Miguel, J.de
  • Schroeder, S.
  • Vergas, J.
  • Téllez, M.J.
  • Vinuesa, D.
  • Muñoz, Lourdes
  • Hernández Quero, José
  • Ferrer, A.
  • Galindo Puerto, María José
  • Ortiz, L.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Montero, M.
  • Blanes, M.
  • Cuellar, S.
  • Lacruz, José
  • Salavert, Miguel|||0000-0002-8571-2124
  • López-Aldeguer, J.
  • Pérez González, Gustavo|||0000-0001-9112-9042
  • Gaspar, G.
  • Yllescas, M.
  • Crespo, P.
  • Aznar, E.
  • Esteban, H.
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Canorea, Isabel
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Quereda, Carmen
  • Sanz, José
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Avellón, Ana|||0000-0003-4425-6350
  • Resino, Salvador|||0000-0001-8783-0450
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multimodal treatment for smoking cessation with varenicline in alcoholic, methadone-maintained, and psychotic patients, A one-year follow-up

  • Raich, Antònia|||0000-0002-8346-864X
  • Pinet, Cristina|||0000-0003-1356-2670
  • Ballbè, Montse|||0000-0002-0747-0924
  • Mondon, Silvia|||0000-0002-9213-5759
  • Tejedor, Rosa
  • Arnau, Anna|||0000-0001-8939-3469
  • Fernández, Esteve|||0000-0003-4239-723X
  • Cano, Margarita
  • Carcolé, Blanca
  • Fernández, Teresa
  • Martínez, Àngela
  • Nieva, Gemma|||0000-0003-2630-1218
  • Roig, Pilar
  • Serra, Imma
  • Serrano, Jaume
Numerous studies have evaluated the efficacy and safety of varenicline for smoking cessation in smokers in the general population and, to a lesser extent, among the psychiatric population. However, few studies have evaluated varenicline in patients with other addictions. The present study was conducted to assess outcomes of a multimodal treatment for smoking cessation intervention with varenicline in a sample of alcohol and substance use disorders and patients with psychotic disorders. This was a prospective, multicenter study. The patient sample comprised alcoholics in remission, methadone-maintained patients, and patients with psychotic disorders, all of whom wanted to stop smoking. All participants received multimodal treatment for smoking cessation therapy (psychological therapy plus varenicline). Smoking abstinence and changes in the psychopathological state of patients were assessed at predefined time points during a 12-month follow-up. The probability of tobacco abstinence after one year of treatment was computed using Kaplan-Meier life tables. The probability of abstinence at one year was 0.225 (95% CI: 0.143-0.319). By group, the probabilities were as follows: patients with psychotic disorders 0.254 (95% CI: 0.118-0.415); alcoholics 0.237 (95% CI: 0.098-0.409); and methadone-maintained patients 0.177 (95% CI: 0.065-0.335). Patients with previous quit attempts had a higher probability of achieving abstinence at one year (p<0.01). The results of this study support the use of multimodal treatment with varenicline in patients with alcohol addiction in remission, patients on methadone maintenance, and patients with stable psychotic disorders. Previous smoking cessation attempts were predictive of smoking cessation success in these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human immunodeficiency virus/hepatits C virus coinfection in Spain, Elimination is feasible, but the burden of residual cirrhosis will be significant

  • Berenguer, Juan|||0000-0001-8541-8200
  • Jarrín, Inma|||0000-0002-7485-2252
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Navarro, Jordi|||0000-0002-7187-0367
  • Téllez, María Jesús
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Iribarren, José Antonio
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Márquez, Manuel A.
  • Artero, Arturo|||0000-0002-7479-3408
  • Morano Amado, Luis Enrique|||0000-0002-0560-3260
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Moreno, Javier Marta
  • Fariñas, Mª Carmen
  • Galindo Puerto, María José
  • Hernando, María Asunción
  • Montero, Marta|||0000-0002-3432-5394
  • Cifuentes, Carmen|||0000-0001-5521-4573
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, José Miguel
  • Domíngez, Lourdes
  • Ferrero, Óscar Luis
  • Fuente, Belén Pizarro de la
  • Herrero Rodríguez, Carmen
  • Reus, Sergio|||0000-0002-3320-9754
  • Hernández Quero, José
  • Gaspar Alonso-Vega, Gabriel|||0000-0002-7144-8959
  • Pérez-Martínez, Laura|||0000-0002-1384-024X
  • García, Coral Fernández
  • Force, Lluís
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Losa-García, Juan Emilio
  • Vilaró, Josep M.
  • Bernal, Enrique|||0000-0002-4041-0579
  • Arponen, Sari
  • Ortí, Amat-Joaquim|||0000-0003-3276-7276
  • Chocarro, Ángel
  • Teira, Ramón M.
  • Alonso, Gerardo
  • Silvariño, Rafael
  • Vegas, Ana
  • Geijo, Paloma
  • Bisbe, Josep
  • Esteban, Herminia
  • González García, Juan|||0000-0002-3652-002X
We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.